In this issue:

Press Release Highlights RSSearch™ Global Expansion and 14,000th Patient Milestone

In case you missed it, a press release highlighting the expansion of RSSearch to the European CyberKnife Center, Munich, Germany and Sir Gairdner Hospital, Perth, Australia was issued July 22, 2014. The addition of these two international centers brings the total of RSSearch participating centers to over 40 centers worldwide. The press release also highlighted a remarkable milestone of reaching 14,000 enrolled patients treated with SRS/SBRT. Deepak Khuntia, M.D., VP of Medical Affairs, Varian Medical Systems commented “Patient registries are becoming an increasingly important component of collecting real-world evidence to understand the effectiveness of treatments and patient outcomes. RSSearch is a platform that will enable physicians world-wide to collaborate to advance the field of SRS and SBRT.”

“Congratulations to RSSearch for reaching these milestones. Patient registries can amass volumes of real-world data from diverse populations to demonstrate the effectiveness of treatment approaches, and help inform emerging best practices in the clinical setting. RSSearch has recently begun drawing from the registry to produce reports that will be broadly useful to the radiosurgery community. Continued good luck in that important process,” commented Professor Eric F. Lartigau, M.D., Acting Chief Medical Officer, Accuray, Inc.

The press release was a success and was picked up by over 275 key industry news/radio/publishing outlets including the Miami Herald, Boston Globe, and DoctorsOutlook.com. For the original version on PRWeb visit: http://www.prweb.com/releases/2014/07/prweb12033600.htm

Recent Update to RSSearch™ Registry

The Radiosurgery Society® continues to strive to improve and update RSSearch, making the Registry more efficient and comprehensive for it’s participants. Over the summer, there have been several updates to RSSearch to allow reporting of patient screening, treatment and follow-up care more effective and reporting of SRS/SBRT treatments all-inclusive. The most recent improvement includes the addition of a drop-down box in the Screening Section that allows users to select a variety of SRS/SBRT technologies used to treat patients. There are now over 18 different pre-selected technologies to choose from. “The expansion of treatment platforms listed in RSSearch exemplifies the RSS’s commitment to supporting the wide-range of SRS/SBRT technologies available to treat patients aimed to improving patient care while promoting SRS/SBRT clinical research through the RSSearch Patient Registry” commented Joanne Davis, Ph.D., Director of Clinical Programs, The RSS. As technologies continue to expand, RSSearch will continue to update the list.

New drop-down feature with expanded list of SRS/SBRT treatment platforms to choose from
Coordinator’s Corner: Meet RSSearch™ Participants

Sir Charles Gairdner Hospital is situated in Perth, Western Australia, and is one of the leading tertiary hospitals in Australia. In 2013, a new outpatient Cancer Centre opened at the Hospital, accommodating approximately 140,000 patient visits each year and consolidating Radiation Oncology, Medical Oncology, Haematology, Adolescent and Young Adult Services, complementary therapies and Allied Health Services.

The Cancer Center at Sir Charles Gairdner Hospital

The Department of Radiation Oncology has six treatment machines, including the first CyberKnife machine in Australia, and provides radiation therapy for over 2,000 patients each year. The CyberKnife machine was commissioned in 2014 and every patient who receives CyberKnife treatment is invited to enroll in the RSSearch Registry.

Participation of the Department of Radiation Oncology in the international Registry has been supported by the Radiation Oncology Consultants and facilitated by the team at the Radiation Oncology Clinical Trials & Research Unit. Clinical Trials Manager, Dr. Mary-Anne Kedda says she is proud to be working with the SCGH Registry team, together with Clinical Trials Coordinators Eva Vosikova, Aylin Yahya and Liz Kernutt, and Research Nurses Claire Haworth, Fiona Baldacchino and Shiro Riunga. The CyberKnife team has demonstrated a strong commitment to patient care.

Radiation Oncologists, Professor Sean Bydder and Dr. Colin Tang believe that the Registry provides an exciting opportunity to examine the results of CyberKnife therapy at our hospital and at other centers around the world.

Support the RSSearch™ Patient Registry Initiative

If you are a Registry participant it is important that you:

- Update your IRB with RSSearch™ protocol and consent forms
- Continue to enter SRS/SBRT screened patients
- Complete screening, treatment and outcome data
- Update patient follow-up information

Become a Registry participant:
- Contact Nalani Brown at nbrown@therss.org

Thank you to our sponsor:

Advertek
Software
Clarity for what’s next.
www.advertek.net
SRS/SBRT Article of Interest:
The intent of this section is to highlight and summarize the results of relevant articles on SRS/SBRT originating from RSSearch™ and elsewhere. If you have an article you would like to submit, please email the RSS at admin@therss.org

Single-fraction radiosurgery for the treatment of renal tumors

In this study by Staehler M. et al, forty patients with renal tumors (11 patients with transitional cell cancer and 29 patients with renal cell cancer) were treated with single-fraction radiosurgery (SRS). All of the patients were indicated as very high-risk candidates for surgery or facing nephrectomy with consecutive hemodialysis. Forty-five renal tumors were treated with 25 Gy delivered in one fraction to the 70% isodose line. The maximum diameter of the renal tumor was 4 cm or less. The median follow-up was 28 months (range 6—78.3 months). The tumor control rate nine months after SRS was 98% with 38 lesions having a reduction in size and 19 complete remissions. Three patients progressed systemically between 3 and 11 months, all of these patients had preexisting metastatic lesions. Toxicity was low with one patient experiencing grade 1 erythroderma, three patients with grade I fatigue and two patients with grade I nausea. In all patients nephrectomy was avoided. Renal function remained stable.

The authors concluded that in this study with short-term results, single-fraction SRS was a safe and efficacious option for selected patients with transitional cell cancer and renal cell cancer. Local control results were similar to other ablative techniques and toxicities were minimal. Potential advantages to single-fraction SRS vs other ablative techniques include the outpatient setting, no anatomical limitations with SRS and no deterioration of renal function in this setting. The authors state further studies are needed to assess the longer-term outcomes of single-fraction SRS for renal tumors.

Frequently Asked Questions & Answers:

Question: What is the MultiPlan XML Parser?
Answer: The MultiPlan XML Parser is an automated process that provides an alternative to manually typing in CyberKnife treatment plan data into the Registry and is compatible to all MultiPlan versions. The RSSearch system allows the upload of plans from the Multiplan system. This is accomplished through a series of steps described in the parser instructions located within the RSSearch Registry system under the "Admin" section, labeled "Multiplan XML Parser." For questions regarding the MultiPlan XML Parser, please contact Nalani Brown at nbrown@therss.org

Question: How can I reach out to other sites about collaborating in research publications out of RSSearch?
Answer: The RSS strongly encourages research and publication collaborations. We consider this one of the key benefits of participation in the RSSearch Registry and in the RSS itself. There are several ways to get involved in research and publication collaborations:

Join in one of the Clinical Research Committees, a working group of physicians, physicists and researchers collaborating together to advance the field of SBRT. Participate by contacting Joanne Davis at jdavis@therss.org

Participating PIs can submit a formal request for data via the RSSearch Data Request Form. This approach yields a variety of benefits including providing you with the numbers of patients currently in the Registry who qualify or meet the requirements of your particular research interest or publication and will also yield the specific sites who have these patients and who therefore might be interested in collaborations. Contact Nalani Brown for more details.